

*ongoing trials - trial from other registries*

## **Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations - Phase 2 - Not yet recruiting**

**Code:** NCT05641298    **Year:** 2022    **Date:**

**Author:** Aceragen

### **Study design (if review, criteria of inclusion for studies)**

Controlled: No.1 Randomised: Yes.2 Open: No.3 Single blind: No.4 Double blind: Yes.5 Parallel group: No.6 Cross over: No

### **Participants**

Principal inclusion criteria: Diagnosis of CF; Age 8-16 years

### **Interventions**

Main objective of the trial: Maximum recommended doses of vitamin D given over two years to children with CF will normalize bone metabolism parameters and improve bone density and skeletal muscle force.

### **Outcome measures**

Primary end point(s): The planned examinations will make it possible to assess the effectiveness of vitamin D substitution, possibly adjust the dose, and further assess the degree of risk of fractures, or to start treatment for osteoporosis.

<https://ClinicalTrials.gov/show/NCT05641298>

### **Keywords**

Bone Density Conservation Agents; Bone Diseases; Gastrointestinal Diseases; Pancreas insufficiency; Pancreatic Diseases; pharmacological\_intervention; Supplementation; vitamins; Vitamin D; Vitamin D Deficiency; Vitamin deficiencies; Malabsorption; Powders;